Although GLP-1 may become a promising therapeutic agent for the treatment of type 2 diabetes mellitus and obesity, these peptide agonists cannot be administered orally due to their peptide nature. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.